Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view.
Today, we are pleased to welcome a guest post from Dr. Barbara Bierer, faculty director of the Multi-Regional Clinical Trials Center of Brigham and Women’s Hospital and Harvard (MRCT Center), a Professor of Medicine, Harvard Medical School and Brigham and Women’s Hospital, Boston and a hematologist/oncologist.
The COVID-19 pandemic is the worst public health emergency the world has encountered in over a century and one that has universally impacted the social, political, economic and medical fabric of our lives; it has also exposed significant and systemic health disparities in health care. The disproportionate rates of infection and of disease-related mortality of people of color have been well-documented. Given these disparities, it is critical that trials for COVID-19 vaccines and therapeutics ensure diverse participation. The few exceptions that have been reported, however, prove that recruitment and retention of underserved populations is possible with effort, planning and intentionality of purpose.
Underrepresentation of diverse participants in clinical trials is not a new phenomenon. Many barriers to equitable inclusion are known (e.g., lack of community involvement, inconvenience and expense of participation), but there has been little forward progress to date. The sobering data from the pandemic coupled with the sociopolitical events in the U.S. that exposed the degree of structural racism may lead us, finally, to a moment of reckoning, a call to action and the motivation to redress health inequalities. The objective of mitigating and eliminating health disparities starts with recognition and with health research that itself will help lead to change—but only with the inclusion of traditionally underserved and underrepresented individuals in research.
The Multi-Regional Clinical Trials Center of Brigham and Women’s Hospital and Harvard (MRCT Center) is a research and policy center created to address the ethics, conduct, oversight and regulatory environment of clinical trials, with a focus on multinational trials. Three years ago, the MRCT Center identified the lack of appropriate diversity in clinical research as a pervasive problem and convened a multi-stakeholder group to address it. In August of 2020, we put forth Achieving Diversity, Inclusion, and Equity in Clinical Research that includes guidance and recommendations as well as practical tools and resources that can be deployed to enhance clinical trial diversity. While affirmative changes can be made by every representative individual and organization in the research enterprise, remediation and success will take time; that success can only be achieved by communication, cooperation, accountability and transparency. The success of each entity is dependent upon others, and we must grow comfortable having often tough conversations in the spirit of helping one another.
This week PhRMA published a strong statement embracing equity, denouncing racism and putting forth actionable commitments endorsed by its member companies. PhRMA has expanded its Principles on Conduct of Clinical Trials to emphasize and strengthen the commitment to diverse inclusion in clinical trials. The MRCT Center applauds the seriousness with which the problem of health inequities is being addressed, including the call for investments in workforce development and professional opportunities, in changes in trial design and conduct, in community engagement and partnership, in education and in infrastructure. None of these initiatives will succeed, however, unless we appreciate our interdependencies and common interests. We are all and each responsible and must stand together for change.
Learn more about these efforts at phrma.org/equity.
Guest Contributor
The PhRMA blog welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view on issues facing our industry and the health care system.
Guest Contributor
ICYMI: PhRMA submits comments to White House on artificial intelligence
New research: Industry sponsored clinical trials contribute billions to state economies
Recent events highlight progress on health equity
ICYMI: PhRMA’s 4th Annual Pathways to Success: Virtual STEM Career Expo
Hispanic Heritage Month: Fighting for Hispanic patients
PhRMA awards grants to 2024 Annual Pathways to Success: Virtual STEM Career Expo Partners
How government price setting fails to address systemic health care inequities
Women’s Health Month: A conversation with Sage
Championing cancer equity: Our drive for healthier AANHPI communities
New analysis: Accelerated approval pathway is changing lives in underserved communities
ICYMI: More evidence of the IRA’s harmful consequences on post-approval research and development
PhRMA provides grant funding to support the Morehouse School of Medicine Satcher Health Leadership Institute’s Health Equity Tra
New social determinants of health simulation explores structural barriers patients face accessing and affording medicines
PhRMA awards grants to 2023 Annual Pathways to Success Graduate Summit Partners
Decentralized clinical trials and the future of drug development
Between hope and despair: Improving cancer outcomes
ICYMI: PhRMA CMO Dr. Michael Ybarra speaks with Dr. Fabian Sandoval about clinical trial diversity
PhRMA awards grant to Emerson Diversity Health Foundation
PhRMA Otorga Beca a la “Emerson Diversity Health Foundation”
PhRMA submits comments to OSTP on enhancing clinical trial diversity
Using traditional HTAs to determine coverage threatens patient access to medicine
Traditional HTAs keep diverse patients out of the conversation
Traditional HTA methods treat everyone like the “average” patient
You won’t fix what you don’t value: Two reasons why traditional cost-effective analyses can perpetuate health inequities
Potential gene therapies bring hope to patients with sickle cell disease
Stephanie Dyson of BMS on reducing health disparities
Sharing rebates can save Americans with diabetes 500 each year and improve adherence
Announcing CAREs Grant Round 4
Announcing CAREs Grant Round 4
Guest Series: PhRMA talks racial and health equity with Lauren Powell, VP US Health Equity and Community Wellness, Takeda
PhRMA awards $75,000 to fund initiatives to reduce health inequities
Watch: Building trust and enhancing clinical trial diversity
More than 800 medicines are in development for diseases that disproportionately affect racial and ethnic communities
PhRMA hosts first stakeholder workshop on clinical trial diversity
PhRMA CAREs Grant request for proposals: Addressing inequities in access to COVID-19 testing, therapeutics and vaccines
PhRMA member companies share how they are improving clinical trial diversity
Guest post: PhRMA talks racial and health equity with Stephanie Dyson, Head of Office at Biogen
Paper finds gaps in health data are a barrier to health equity
New research shows hotspots of inequity relate to increased COVID-19 hospitalizations
Increasing diversity at investigator sites could increase minority participation in clinical trials
Report highlights biopharmaceutical industry’s commitment to D&I
Strengthening a culture dedicated to patients and equity: A conversation with Percival Barretto-Ko, President of Astellas US
PhRMA CAREs Grant request for proposals: Addressing racial disparities in medication utilization and adherence
Just released: PhRMA members’ new clinical trial diversity principles
ICYMI: Addressing health inequities: Biopharmaceutical companies are rising to the occasion
Guest Post: Honoring Hispanic Heritage Month by taking action on health equity
Sharing rebates can improve access to medicines and increase health equity
PhRMA will continue to advocate for equity within our industry
Three ways the pharmaceutical industry can positively impact health equity
Guest Post: Amgen Foundation stands for equal opportunities in STEM learning
Systemic racism is as real as any disease, and our industry is not immune
Guest Post: Pride started with protest: Combatting the dual pandemics of COVID-19 and racism this Pride Month
How biopharmaceutical researchers are ensuring COVID-19 vaccines will be safe and effective
PhRMA awards $100,000 to fund projects that address health inequalities
Clinical Trials Awareness Week: Recognizing unsung heroes in medical research
Guest Post: Preserving clinical research sites during the coronavirus pandemic
Observing National Minority Health Month in the age of COVID-19
The biopharmaceutical industry’s unique role in responding to COVID-19
COVID-19 Response: Supporting the frontline
America’s biopharmaceutical companies are working around the clock to beat coronavirus
ICYMI: America’s biopharmaceutical companies are taking on COVID-19
Clinical Trials Awareness Week: Celebrating innovation in clinical research
Clinical trials impact state economies
Examining the truth behind clinical trial costs
New report details the setbacks and challenges to Alzheimer’s research
Guest post: Ensuring communities have a seat at the table: The importance of diversity in clinical trials
Bringing innovation to clinical trial design
EFPIA-PhRMA Principles successfully enable responsible clinical trial data sharing
Guest Post: Film chronicles clinical trials ‘paying it forward’
Biopharmaceutical industry policies aim to increase access to clinical trial data
Guest Post: The Clinical trial experience from a patient & researcher perspective
Guest Post: Patients as research partners - Rethinking patient access to clinical trial data
Guest Post: Spotlighting the heroes in clinical trials
Guest Post: Advancing oncology research through clinical trials
Clinical Trials Awareness Week: Celebrating the impact of clinical research
Driving innovation through collaboration
Watch: Biomarkers in drug development with Dr. Bernie Zeiher
"Committing to diversity, equity and inclusion: A call to action for clinical trials"
Clinical Trials
Health Equity
Committing to diversity, equity and inclusion: A call to action for clinical trials
"Committing to diversity, equity and inclusion: A call to action for clinical trials"